Agios Pharmaceuticals, Inc. (AGIO)

25.55 -0.60 (-2.29%) At close: 04:00PM EDT

Agios Pharmaceuticals, Inc.

88 Sidney Street
2nd Floor
Cambridge, MA 02139-4169
United States
617 649 8600
https://www.agios.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 390

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jonathan Biller J.D.	CFO & Head of Corp. Affairs	804.18k	N/A	1965
Dr. Bruce Car Ph.D.	Consultant	776.12k	N/A	1962
Dr. Sarah Gheuens M.D., Ph.D.	Chief Medical Officer and Head of R&D	1.57M	72.32k	1980
Ms. Richa Poddar	Chief Commercial Officer	624.08k	N/A	1982
Mr. Brian M. Goff M.B.A.	CEO & Director	N/A	N/A	1969
Dr. Lewis Clayton Cantley Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Craig B. Thompson M.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	1953
Dr. Shin-San Su Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1956
Mr. T. J. Washburn Jr.	Principal Accounting Officer	N/A	N/A	1981

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 31 July 2022 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.